Democratic Drug Pricing Push: Starting And Ending With Insulin?
When the Democratic party regained control of the US House of Representatives in 2019, their push to enact comprehensive drug pricing legislation began with a hearing on insulin. After four years, it might be ending with insulin as the sole focus after all.
You may also be interested in...
Advocates for drug pricing reform don’t have much in the way of price increases to complain about at the moment – but they argue that the price hikes they are seeing suggest a growing confidence among manufacturers that the threat of drug pricing reform is subsiding.
The non-profit organization plans to make biosimilar versions of Lantus, Humalog and Novolog and sell them for no more than $30/vial.
The president’s state of the union address comes after a year of mostly disappointing efforts for the administration on COVID and drug pricing.